Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KUR 111

Drug Profile

KUR 111

Alternative Names: I-0401

Latest Information Update: 30 Jun 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kuros Biosurgery
  • Developer Kuros Biosciences
  • Class Blood proteins; Peptides
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Fracture

Most Recent Events

  • 30 Jun 2016 KUR 111 is available for licensing as of 28 Jun 2016. http://www.kuros.ch/
  • 09 Oct 2015 Efficacy and adverse events data from a phase IIb trial in Fractures released by Kuros
  • 19 Aug 2015 KUR 111 is still in phase II trials for Fracture in Australia, Canada and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top